**Core Concept**
The regulation of cholesterol synthesis involves a series of enzyme-catalyzed reactions, with HMG CoA reductase serving as a key regulatory step. This enzyme catalyzes the conversion of HMG CoA to mevalonate, a crucial step in the mevalonate pathway, which is the primary route for cholesterol biosynthesis.

**Why the Correct Answer is Right**
HMG CoA reductase is a rate-limiting enzyme in the cholesterol biosynthesis pathway. It is a target for statins, a class of lipid-lowering medications that inhibit this enzyme, thereby reducing cholesterol production in the liver. The enzyme uses NADPH as a cofactor and is activated by phosphorylation. This regulatory step is critical for maintaining cholesterol homeostasis, as excessive cholesterol production can lead to hypercholesterolemia and associated cardiovascular risks.

**Why Each Wrong Option is Incorrect**
**Option A:** HMG CoA synthase is an enzyme that catalyzes the condensation of acetyl-CoA and acetoacetyl-CoA to form HMG CoA, but it is not the primary regulatory step in cholesterol synthesis.

**Option C:** Phosphomevalonate kinase is an enzyme that catalyzes the phosphorylation of mevalonate to form phosphomevalonate, but it is not a key regulatory step in the cholesterol biosynthesis pathway.

**Option D:** Diphosphomevalonokinase is an enzyme that catalyzes the decarboxylation of 5-phosphomevalonate to form isopentenyl pyrophosphate, a crucial intermediate in cholesterol synthesis, but it is not the primary regulatory step.

**Clinical Pearl / High-Yield Fact**
Statins, which inhibit HMG CoA reductase, are effective in reducing cardiovascular events by lowering LDL cholesterol levels. However, they can also have off-target effects, including muscle toxicity and increased risk of diabetes.

✓ Correct Answer: B. HMG CoA reductase